Zydus and XOMA Announce IL-2-Based Immuno-Oncology Therapy Licensing Agreement
Zydus Cadila, an innovation-driven global pharmaceutical company, and XOMA Corporation announced they have entered into a licensing agreement to advance an IL-2-based immuno-oncology…
Read More...
Read More...
